Immutep (IMMP) has released an update.
Immutep Limited has partnered with the Centre for Human Drug Research to conduct a pioneering Phase I study of IMP761, a novel LAG-3 agonist antibody aimed at treating autoimmune diseases by restoring immune system balance. The clinical trial, slated to begin in mid-2024, will involve approximately 49 healthy volunteers to evaluate the safety and pharmacological activity of the treatment. IMP761 represents a significant advancement in immunotherapy, with potential to modify the treatment landscape for various autoimmune disorders by selectively inhibiting overactive autoimmune memory T cells.
For further insights into IMMP stock, check out TipRanks’ Stock Analysis page.
